Using heart tissue and blood to predict dangerous events in hypertrophic cardiomyopathy

Transcriptomics, pathobiology, and cardiac event in hypertrophic cardiomyopathy

NIH-funded research Columbia University Health Sciences · NIH-11089337

This project looks at RNA patterns in heart tissue and blood from people with hypertrophic cardiomyopathy to find signals that predict dangerous events like arrhythmias, heart failure, or sudden death.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionColumbia University Health Sciences NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11089337 on NIH RePORTER

What this research studies

You would be part of a large Harvard–Columbia biorepository of people with hypertrophic cardiomyopathy where researchers already collected blood from over 600 patients and heart muscle from about 120. The team will measure RNA signals (transcriptomics) in both the heart tissue and plasma and compare those patterns to who develops major adverse cardiovascular events (MACE). They will link molecular findings to clinical data gathered by regular interviews, medical record reviews, and yearly in-person exams. The goal is to find biological pathways and blood markers that relate to disease status and future dangerous heart events.

Who could benefit from this research

Good fit: Adults with a diagnosis of hypertrophic cardiomyopathy who can provide blood samples and, if undergoing clinical heart surgery, may be able to donate myocardial tissue and participate in follow-up visits.

Not a fit: People without HCM, those unable or unwilling to provide samples or attend follow-up, or those seeking an immediate treatment benefit are unlikely to gain direct benefit from participation.

Why it matters

Potential benefit: If successful, this work could help doctors identify which HCM patients are most likely to have serious heart events and guide more personalized preventive care.

How similar studies have performed: Previous genetic and biomarker studies have improved HCM risk understanding, but using paired heart-tissue and blood transcriptomics to predict events is a relatively new approach.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cardiac DiseasesCardiac Disorders
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.